Triple Effect of Doxorubicin, 5-Fluorouracil, Propranolol on Cell Survival on MCF-7 Breast Cancer Cell Line

Abstract

Purpose: Investigating the triple effect of doxorubicin, 5-fluorouracil, propranolol on MCF-7 (ER+, WTp53) breast cancer cell line with MTT test and survival analysis. Materials/Methods: In order to determine effective dosages of a combination of doxorubicin, 5-fluorouracil, propranolol on the MCF-7 cell line by using MTT and survival analysis technique. Result: IC 50 values acquired by MTT tests are 0.01 mg/ml for doxorubicin, 6 mg/ml for 5-fluorouracil, 30 mg/ml for propranolol and 0.2/1/30 mg/ml (with previous respect) if all three agents are combined. It is found that the use of doxorubicin, 5-fluorouracil, and propranolol in combination is much effective than their single application. Discussion: Moderate concentrations of doxorubicin, 5-fluorouracil, and propranolol, if they are applied individually, showed high toxicity. When we used these drugs in combination; toxic effects lessened with respect to monotherapy. In the MCF-7 cell line, doxorubicin (IC 50 : 0.01 µM) increases cell death rates significantly and propranolol (IC 50 : 3 µM) has minimum effects in monotherapy in contrast to others. Propranolol is only superior to itself in combination therapy (IC 50 : 4 µM). However 5-fluorouracil (IC 50 : 30 µM) showed antagonistic effects with respect to other drugs. Additionally, having applied the three drugs in combination on the MCF-7 cell line for the first time in literature, it is highly possible to assess the application of doxorubicin, 5-fluorouracil and propranolol combination as a novel therapy option.

Antitumor activities of carboplatin–doxorubicin–ZnO complexes in different human cancer cell lines (breast, cervix uteri, colon, liver and oral) under UV exposition

“…RGDfC-Se Derlin1-siRNA ¼ 200 nM Xia et al [7] Human liver cancer cells (HepG2) Galactose-Se Doxorubicin ¼ 4 lg/mL Xia et al [8] Cervical cancer cells (HeLa) Hyaluronic acid-Se Doxorubicin ¼ 4 lg/mL Vu et al [9] Human myeloid leukaemia -Doxorubicin ¼ 0.5-1 lg/mL Malky et al [10] Human breast adenocarcinoma (MCF-7) -Doxorubicin ¼ 0.25-1 lg/mL Christowitz et al [11] Murine breast tumour (E0771) -Doxorubicin ¼ 6-15 mg/mL Al-Harthy et al [12] Human breast adenocarcinoma (MCF-7) -Doxorubicin ¼ 13-36 lg/mL Matcovschii et al [13] Human glioblastoma -Doxorubicin ¼ 2-20 lg/mL Allen et al [14] Mouse gonads -Carboplatin ¼ 0.1-1 lg/mL Cisplatin ¼ 0.5-5 lg/mL Kuittinen et al [15] Ovarian cancer cells -Carboplatin ¼ 0.1-50 lg/mL Paclitaxel ¼ 1-10 ng/mL Corn et al [16] Human prostate cancer -Carboplatin ¼ 3-4 mg/mL Cabazitaxel ¼ 20-25 mg/mL Lopes et al [17] Human and mouse ovary -Doxorubicin ¼ 1-2 lg/mL Cisplatin ¼ 5-10 lg/mL Yu et al [18] Bladder cancer (MBT-2) -Doxorubicin ¼ 0.62 lg/mL Lipodoxorubicin ¼ 130 lg/mL Eroglu et al [19] Human breast adenocarcinoma (MCF-7) -Doxorubicin ¼ 0.01 mg/mL 5-Fluorouracil ¼ 6 mg/mL Propranolol ¼ 30 mg/mL Escobar-Resendiz et al [20] Human lung carcinoma cell (A549)…”

“…Sometimes, administering single chemo drugs for a long period of time is a challenging task because of the development of chemoresistance and severe side effects [1][2][3][4][5][6][7][8][9][10][11][12][13]. A double-chemo drug regimen is sufficient for very small tumours [14][15][16][17][18], whereas other chemo drugs might be used if these methodologies are not effective [19,20]. Meanwhile, some research progress has been made in nanoparticle-assisted drug delivery systems with different dosages for better treatment of cancer [2][3][4][5][6][7][8].…”

Ellajik Asidin İnsan Akciğer Kanseri Üzerine Antiproliferatif Etkinliklerinin İn Vitro Araştırılması

“…Following the incubation, 20 µL / well of MTT solution (5 mg / mL) was added and allowed to incubation further during 3 hours. At the end of incubation, MTT dye was dissolved by adding DMSO (200 µL / well) and plates were read on plate reader (HTX Synergy, BioTek, USA) at a wavelength of 570 nm (n = 3) [6]. The percentages of viability were calculated relative to the untreated group of cells.…”

A study with cancer stem cells and three-dimensional tumoroids: investigation of the combined effects of 5-fluorouracil and doxorubicin in breast cancer

“…Breast cancer (BC) is the leading cancer cause of death among women all over the world [ 1 ]. Chemotherapeutic combinations (polychemotherapy) have recently included in treatment plans of its [ 2 , 3 ]. Breast stem cells are now associated with cancer stem cells (CSC), which are known to be highly effective in oncological processes and have been identified in many types of cancer [ 4 ].…”